Business Description
Enwei Pharmaceutical Co Ltd
ISIN : CNE100005LC7
Share Class Description:
SZSE:301331: Class ACompare
Compare
Traded in other countries / regions
301331.China IPO Date
2022-09-21Description
Enwei Pharmaceutical Co Ltd is engaged in the research and development, production and sales of proprietary Chinese medicines and chemical medicines.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.5 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | 4.39 | |||||
| Interest Coverage | 4.15 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.74 | |||||
| Beneish M-Score | -3.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4.5 | |||||
| 3-Year EBITDA Growth Rate | -15.4 | |||||
| 3-Year EPS without NRI Growth Rate | -19.3 | |||||
| 3-Year Book Growth Rate | 12.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 95.91 | |||||
| 9-Day RSI | 87.63 | |||||
| 14-Day RSI | 79.55 | |||||
| 6-1 Month Momentum % | -10.03 | |||||
| 12-1 Month Momentum % | -26.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.27 | |||||
| Quick Ratio | 3.67 | |||||
| Cash Ratio | 2.58 | |||||
| Days Inventory | 116.33 | |||||
| Days Sales Outstanding | 47.7 | |||||
| Days Payable | 36.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.93 | |||||
| Dividend Payout Ratio | 1.98 | |||||
| Forward Dividend Yield % | 2.93 | |||||
| 5-Year Yield-on-Cost % | 2.93 | |||||
| 3-Year Average Share Buyback Ratio | -10.1 | |||||
| Shareholder Yield % | 3.37 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.55 | |||||
| Operating Margin % | 6.01 | |||||
| Net Margin % | 5.18 | |||||
| FCF Margin % | -0.69 | |||||
| ROE % | 3.72 | |||||
| ROA % | 2.96 | |||||
| ROIC % | 5.24 | |||||
| 3-Year ROIIC % | -13.91 | |||||
| ROC (Joel Greenblatt) % | 18.89 | |||||
| ROCE % | 4.36 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 70.65 | |||||
| PE Ratio without NRI | 67.5 | |||||
| PS Ratio | 3.61 | |||||
| PB Ratio | 2.77 | |||||
| Price-to-Tangible-Book | 3.63 | |||||
| Price-to-Operating-Cash-Flow | 19.37 | |||||
| EV-to-EBIT | 41.81 | |||||
| EV-to-EBITDA | 41.81 | |||||
| EV-to-Revenue | 2.71 | |||||
| EV-to-FCF | -394.56 | |||||
| Price-to-Graham-Number | 3.3 | |||||
| Price-to-Net-Current-Asset-Value | 6.11 | |||||
| Price-to-Net-Cash | 29.32 | |||||
| Earnings Yield (Greenblatt) % | 2.39 | |||||
| FCF Yield % | -0.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enwei Pharmaceutical Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 778.093 | ||
| EPS (TTM) (Â¥) | 0.386 | ||
| Beta | 0 | ||
| Volatility % | 42.28 | ||
| 14-Day RSI | 79.55 | ||
| 14-Day ATR (Â¥) | 1.128236 | ||
| 20-Day SMA (Â¥) | 22.141 | ||
| 12-1 Month Momentum % | -26.98 | ||
| 52-Week Range (Â¥) | 18.885135 - 32.087837 | ||
| Shares Outstanding (Mil) | 102.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enwei Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enwei Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Enwei Pharmaceutical Co Ltd Frequently Asked Questions
What is Enwei Pharmaceutical Co Ltd(SZSE:301331)'s stock price today?
The current price of SZSE:301331 is ¥27.27. The 52 week high of SZSE:301331 is ¥32.09 and 52 week low is ¥18.89.
When is next earnings date of Enwei Pharmaceutical Co Ltd(SZSE:301331)?
The next earnings date of Enwei Pharmaceutical Co Ltd(SZSE:301331) is .
Does Enwei Pharmaceutical Co Ltd(SZSE:301331) pay dividends? If so, how much?
The Dividend Yield %  of Enwei Pharmaceutical Co Ltd(SZSE:301331) is 2.93% (As of Today), Highest Dividend Payout Ratio of Enwei Pharmaceutical Co Ltd(SZSE:301331) was 1.98. The lowest was 1.53. And the median was 1.53. The  Forward Dividend Yield % of Enwei Pharmaceutical Co Ltd(SZSE:301331) is 2.93%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers